Pfizer Raises 2025 EPS Outlook Despite Revenue Headwinds—Obesity Push and Cost Savings Drive Optimism

Strong Non-COVID Portfolio Growth Offsets COVID Declines

Pfizer’s third-quarter 2025 report painted a mixed but constructive picture for investors. While total revenues slipped 6% year-over-year to $16.65 billion—driven by lower COVID product sales—the underlying business posted solid progress, especially across non-COVID products. Notably, operational revenue for this non-COVID portfolio grew 4%, driven by high-demand franchises like Eliquis, Vyndaqel, and Nurtec ODT/Vydura.

This revenue mix shift—away from pandemic-era highs—underlines the company’s adaptation to an evolving healthcare landscape and emphasizes more stable, long-term growth drivers. For the first nine months of 2025, overall revenue dipped just 2% compared to the prior year, showing relative resilience amid major pandemic tailwinds unwinding.

EPS Guidance Lift Reflects Efficiency and Strategic Momentum

Despite near-term COVID drag, Pfizer lifted and narrowed its 2025 adjusted diluted EPS guidance to $3.00–$3.15 (previously $2.90–$3.10), a sign of both cost control and confidence in execution. This optimism is grounded in strong YTD performance and progress toward delivering roughly $7.2 billion in anticipated net cost savings by 2027. Productivity gains—driven by leaner cost structures and R&D focus—are translating directly to margin expansion.

Key Business Drivers: Strategic Acquisitions and Cost Management

Pfizer is doubling down on high-growth markets, notably obesity and cardiometabolic disease, with the $4.9 billion acquisition of Metsera. Early regulatory approval from the FTC signals rapid integration—and if milestone payouts for Metsera are achieved, Pfizer’s pipeline could benefit from first-in-class, next-generation obesity drugs. Combined with an historic US government agreement providing pricing clarity and discount access for American patients, Pfizer is laying foundations for longer-term earnings stability.

In parallel, cost controls are kicking in across the business. For Q3 2025, adjusted cost of sales dropped 18% year-over-year, with operating expense reductions across SI&A and R&D. Even with a $1.35 billion R&D charge (impacting EPS by $0.20), the underlying cost improvement story is robust, freeing up capital for innovation and shareholder returns (notably, $7.3 billion paid in cash dividends so far in 2025).

Pipeline Milestones Add to Long-Term Growth Narrative

The company reported clinical wins in several blockbuster candidates. Recent positive phase 3 results for Padcev in muscle-invasive bladder cancer (cutting the risk of recurrence, progression, or death by 60%), Tukysa in HER2+ metastatic breast cancer (statistically significant improvement in PFS), and Xtandi in non-metastatic hormone-sensitive prostate cancer (40.3% lower risk of death) all strengthen the pipeline’s commercial appeal.

Comirnaty’s next-generation COVID-19 vaccine received both positive trial results and expanded regulatory support, keeping it relevant as COVID becomes endemic and seasonal. However, legacy COVID revenues for Paxlovid and Comirnaty both fell sharply (-55% and -20%, respectively) versus a year ago—a reality Pfizer is offsetting by diversification into high-demand therapeutic categories.

US Pricing Agreement and Metsera Deal Provide Visibility

Pfizer’s voluntary agreement with the US government—a first in its industry—locks in favorable drug pricing and direct purchasing for American patients. Most core products and select specialty brands will now be available with average discounts around 50%, in exchange for a three-year tariff grace period and ongoing US manufacturing investments. Meanwhile, legal action to defend the Metsera deal underscores how critical this pipeline addition is to Pfizer’s future strategy in obesity—a segment many investors see as pharma’s next big battleground.

Takeaway: Strategic Repositioning and Expense Discipline Offset Revenue Volatility

While the era of COVID windfalls is over, Pfizer’s new story is about disciplined execution, emerging franchises in growth markets, and improved earnings quality. The raised and narrowed 2025 EPS guidance speaks volumes about the effectiveness of management’s strategy and ongoing transformation. Shareholders get not just improved visibility—but also a retooled business ready to compete for new opportunities as the industry landscape evolves.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI